Study #2020-0971
Itacitinib to Prevent Graft Versus Host Disease
MD Anderson Study Status
Not Accepting
Treatment Agent
Busulfan, Cyclophosphamide, Fludarabine, Itacitinib, Tacrolimus, Thiotepa
Description
This phase II trial studies if itacitinib plus standard of care treatment may help prevent graft-versus-host-disease (GVHD) in patients who have received an allogeneic (donor) stem cell transplant. An allogeneic transplant uses blood-making cells from a family member or unrelated donor to remove and replace a patient's abnormal blood cells. Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Giving itacitinib with standard of care treatment after the transplant may stop this from happening.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hematologic and Lymphocytic Disorder
Study phase:
Phase I
Physician name:
Uday Popat
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-844-338-0349
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.